Could a simple pill replace daily shots for clot prevention after cancer surgery?

NCT ID NCT07189897

Recruiting now Disease control Sponsor: Kiranya Arnold Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether apixaban (a pill taken twice a day) is a safe and more satisfying alternative to enoxaparin (a daily shot) for preventing blood clots after head and neck cancer surgery. About 76 adults will take one of the two medicines for 10 days after surgery. Researchers will track side effects, patient satisfaction, and how well participants stick to the treatment plan.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: apixaban (pill) and enoxaparin (shot)
What this could lead to: If successful, this could show that a simple pill is a safe and more convenient alternative to daily shots for preventing blood clots after head and neck cancer surgery.
What could go wrong: This is a small pilot study (76 people), so results may not apply to everyone. It compares two existing drugs, not a new breakthrough, and side effects are possible with both.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms thrombotic disease venous thromboembolism prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK CANCER VENOUS THROMBOEMBOLISM

Contacts and locations

Locations

SUNY Upstate
RECRUITING

Syracuse, New York, 13210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.